Published on 21/12/2025
Implementing Decentralized and Hybrid Clinical Trial Models in Phase 2 Studies
Introduction
The traditional site-centric model of clinical trials is evolving rapidly. With the advancement of digital health technologies and the impact of global health crises like COVID-19, sponsors and regulators have embraced decentralized clinical trials (DCTs) and hybrid trial models. In Phase 2 trials—where efficacy signals are explored, and patient engagement is vital—these models offer flexibility, improved recruitment, and enhanced data capture. This tutorial explains the structure, benefits, and challenges of decentralized and hybrid trial designs in Phase 2.
What Is a Decentralized Clinical Trial (DCT)?
A decentralized clinical trial conducts some or all trial activities remotely, using digital tools and telemedicine rather than traditional in-person site visits. Components can include:
- Remote informed consent (eConsent)
- Telemedicine consultations
- Home health visits and mobile nursing
- Wearable devices for monitoring
- Direct-to-patient drug shipping
What Is a Hybrid Trial?
A hybrid trial combines decentralized elements with traditional on-site procedures. For example, while screening may occur in person, follow-ups may be conducted remotely.
Why Use DCTs or Hybrid Models in Phase 2?
- Improves recruitment and retention: Reduces travel and site burden for patients
- Enables broader reach: Access to rural and underrepresented populations
- Real-time data capture: Wearables and ePROs
Elements of a Phase 2 Decentralized or Hybrid Trial
1. eConsent Platforms
- Enable patients to review and sign ICFs remotely
- Must be IRB/EC-approved and compliant with 21 CFR Part 11
2. Telehealth Visits
- Used for non-invasive procedures and patient counseling
- Must be secure and HIPAA/GDPR-compliant
3. Remote Data Collection
- Use of eDiaries, ePROs (Patient-Reported Outcomes), and connected devices
- Examples: Smartwatches, glucose monitors, blood pressure cuffs
4. Home Health Services
- Trained professionals conduct lab sample collection, drug administration, or physical exams at home
5. Direct-to-Patient (DTP) Drug Delivery
- Ensures patient access to investigational product without site visit
- Requires temperature-controlled shipping and traceability
Technology Infrastructure Required
- eSource platforms (to capture data from multiple sources)
- eCRF integration with wearable and app data
- Centralized monitoring dashboards and alerts
Case Example: Hybrid Phase 2 Trial in Neurology
A biotech company studying an investigational treatment for Parkinson’s disease used a hybrid model: baseline visits and MRI scans occurred in clinic, while weekly assessments (mobility, tremor, fatigue) were conducted via smartwatch and ePRO apps. This model reduced patient dropout by 40% compared to a previous Phase 1 study.
Regulatory Perspectives
FDA (U.S.)
- Encourages DCT innovation through guidance on remote consent, monitoring, and home-based trials
- Supports use of digital health technologies in early-phase studies
EMA (Europe)
- Favors hybrid models over fully decentralized in early development
- Requires risk mitigation and traceability for home drug administration
CDSCO (India)
- Still cautious about full decentralization
- Approves elements like eConsent and ePRO with EC and DCGI clearance
Challenges of DCTs in Phase 2
- Data standardization: Merging wearable and clinical data can be complex
- Protocol design: Requires digital-first thinking and flexibility
- Regulatory alignment: Varies greatly by region
- Patient tech literacy: Training and support are essential
Best Practices for Sponsors
- Start with a hybrid approach and scale as feasible
- Involve patients in trial design for usability feedback
- Use decentralized components to reduce dropouts and expand reach
- Ensure technology vendors are validated and compliant
- Submit detailed DCT plans to regulators early for feedback
Conclusion
Decentralized and hybrid models are redefining how Phase 2 trials are conducted. When implemented thoughtfully, these models enhance patient access, improve data collection, and reduce study burden. Sponsors embracing digital tools and remote strategies must ensure proper planning, training, and regulatory alignment to maximize trial success. As digital adoption grows, hybrid trials are likely to become the norm rather than the exception.